Business
SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference
Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth Liquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow
About this update from Sophia Genetics Sa
[{"type":"text","content":"Strong SOPHiA DDM™ adoption and analysis volume contributes to continued revenue growth \nLiquid biopsy and HRD on SOPHiA DDM™ Platform continue to grow year-over-year, with Tennessee Oncology, Dasa and The Royal Marsden announced today\nBOSTON and ROLLE, Switzerland, Jan. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, will share an overview of its near-term growth strategy, fueled by strong adoption and opportunity for the SOPHiA DDM™ Platform, in a presentation at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 a.m. PST.\n\n \n \n \n \n \n \n\n \nHighlights include: \nContinued adoption of SOPHiA DDM™ in clinical markets globally has enabled analysis volume for the full year of 2023 to grow to a record 315,000+ analyses globally1.Since inception, the Platform has analyzed over 1.5 million genomic profiles worldwide.New customer count for 2023 includes 87 core genomics customers globally2, resulting in a current network of 750+ customers using SOPHiA DDM™ globally3.New U.S.-based customer Tennessee Oncology exploring MSK-ACCESS® powered with SOPHiA DDM™, as well as Latin American healthcare network Dasa expanding to incorporate the liquid biopsy application. The Royal Marsden, a world leader in cancer care based in the U.K., is live on the SOPHiA DDM™ Platform to support HRD testing and research.CEO Commentary\"We have witnessed the market demand for a global, decentralized technology platform that will power the precision medicine space at-scale – a $40 billion total addressable market between clinical and biopharma markets. The continued adoption of SOPHiA DDM™ and the record number of analyses performed on the platform, increasing year-over-year, reflects how SOPHiA DDM™ is positioned to fulfill that need for those markets. We are especially positioned for growth with our HRD and Liquid Biopsy applications, which have both grown significantly year-over-year. I could not be more excited about the opportunities that lie ahead and SOPHiA GENETICS' ability to capitalize,\" said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder of SOPHiA GENETICS. \"With our commitment to financial discipline and our strategic vision that will help us continue on the path to democratizing data-driven medicine, we expe...